Catherine Knupp - Zoetis President

ZTS -- USA Stock  

Fiscal Quarter End: December 31, 2019  

Dr. Catherine A. Knupp is Executive Vice President, President Research and Development of Zoetis Inc. Dr. Knupp has served as our Executive Vice President and President of Research and Development since October 2012. From 2005 to 2012, she served as Vice President of Pfizers Veterinary Medicine Research and Development business unit. Dr. Knupp joined Pfizer in July 2001 and held various positions, including Vice President of Pfizers Michigan laboratories for Pharmacokinetics, Dynamics and Metabolism.
Age: 57  President Since 2012  Ph.D    
973 822-7000
Knupp earned her Doctor of Veterinary Medicine degree in 1985 from the University of Illinois, where she also received a master degree in toxicology and a bachelor degree in veterinary biosciences. She also earned another bachelor degree in chemistry from Western Illinois University.

Catherine Knupp Latest Insider Activity

Management Efficiency

The company has Return on Asset of 11.71 % which means that on every $100 spent on asset it made $11.71 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 60.93 % implying that it generated $60.93 on every 100 dollars invested.
The company has 6.66 B in debt with debt to equity (D/E) ratio of 248.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.3 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Jeffrey NeedhamPerrigo Company Plc
John WesolowskiPerrigo Company Plc
John HendricksonPerrigo Company Plc
Ganadhish KamatDr Reddys Laboratories Ltd
Thomas GraneyVertex Pharmaceuticals Incorpor
K RaoDr Reddys Laboratories Ltd
Amit SachdevVertex Pharmaceuticals Incorpor
Paul SilvaVertex Pharmaceuticals Incorpor
Ian SmithVertex Pharmaceuticals Incorpor
Michael StewartPerrigo Company Plc
Amit BiswasDr Reddys Laboratories Ltd
Raghav ChariDr Reddys Laboratories Ltd
George YancopoulosRegeneron Pharmaceuticals
Kimberly WhiteVertex Pharmaceuticals Incorpor
Joseph LaRosaRegeneron Pharmaceuticals
Christopher FenimoreRegeneron Pharmaceuticals
J RamachandranDr Reddys Laboratories Ltd
Daniel PlewRegeneron Pharmaceuticals
Michael PariniVertex Pharmaceuticals Incorpor
John GrayVertex Pharmaceuticals Incorpor
Jay MarkowitzRegeneron Pharmaceuticals

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drugs - Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Return On Equity60.93
Return On Asset11.71
Profit Margin23.76
Operating Margin39.29
Current Valuation60.95 B
Shares Outstanding477.56 M